More issues

The Requirements Checklist to Get Fintepla (fenfluramine) Covered by UnitedHealthcare in New York: Forms, Appeals, and REMS Documentation

Answer Box: Getting Fintepla Covered by UnitedHealthcare in New York To get Fintepla (fenfluramine) covered by UnitedHealthcare in New York: First, enroll in the mandatory Fintepla REMS program and complete baseline echocardiography. Then submit prior authorization through UnitedHealthcare's provider portal with diagnosis confirmation (ICD-10 G40.83 for Dravet
5 min read

Myths vs. Facts: Getting Vigabatrin (Sabril) Covered by Humana in Washington - Complete Appeal Guide

Answer Box: Getting Vigabatrin Covered by Humana in Washington Eligibility: Humana requires prior authorization for vigabatrin (generic) and Sabril (brand) for infantile spasms and refractory seizures, with mandatory REMS program enrollment for prescriber, pharmacy, and patient before coverage consideration. Fastest path to approval: 1. Complete REMS enrollment at vigabatrinrems.com
5 min read

How to Get Humate-P (Antihemophilic Factor/vWF Complex) Covered by Aetna CVS Health in Michigan: Complete Appeals Guide

Answer Box: Fast Track to Humate-P Coverage Humate-P requires prior authorization from Aetna CVS Health in Michigan. Submit via the Aetna provider portal with hematologist consultation, VWF labs, and desmopressin trial documentation (if applicable). Standard decisions take 7-14 days; expedited reviews complete within 72 hours for urgent cases. If denied,
6 min read

UnitedHealthcare's Coverage Criteria for Koselugo (Selumetinib) in New Jersey: What Counts as "Medically Necessary"?

Answer Box: Getting Koselugo Covered by UnitedHealthcare in New Jersey UnitedHealthcare requires prior authorization for Koselugo (selumetinib) under both medical and pharmacy benefits, with no step therapy requirements for pediatric NF1 plexiform neurofibromas. Medical necessity requires confirmed NF1 diagnosis with symptomatic, inoperable plexiform neurofibromas, baseline LVEF assessment, and ophthalmologic evaluation.
5 min read